Acute coronary syndromes: pathology, diagnosis, genetics, prevention, and treatment.

An acute coronary syndrome (ACS) is the most ominous manifestation of coronary artery disease (CAD). The burden of ACS and its impact are striking. Cardiovascular disease is now the most common cause of mortality worldwide, and among cardiovascular deaths, the majority are attributable to CAD.1 As a result, although CAD in general is a major global public health concern, ACS is particularly worrisome because it is both prevalent but at the same time portends a poor prognosis. Although advanced therapies may alleviate ACS-related morbidity and mortality in well-served communities located in affluent countries, many persons in less-fortunate situations living in low- and middle-income countries remain exposed to the ravages of this disease. Despite this outlook, rapid progress is being made in understanding the pathology, in prevention, and in treatment of ACS. As readers will find even by perusing the headings of the articles in this ACS Compendium, there is much to be optimistic about. As Editors of this ACS Compendium, we are privileged to have played a small role in helping to provide the framework for the esteemed authorship groups to leverage their collective expertise and provide for us a definitive overall review of ACS. In working with these world-renown scientists and clinicians on this collection of ACS articles, which also included a cadre of expert reviewers (to who we are especially thankful), we found ourselves in the enviable position of being privy to a deeply insightful, cutting-edge, and forward-looking appraisal of the current state-of-the-science for ACS. Although this fund of knowledge is clearly set out in the articles that follow, several unexpected points arose from these interactions. The most obvious, somewhat surprisingly, was the question of what exactly is an ACS? The term ACS appeared relatively recently in the medical lexicon. A simple search in PubMed reveals that …

[1]  M. Pfeffer,et al.  A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.

[2]  A. Íñiguez,et al.  Effect of Early Metoprolol on Infarct Size in ST-Segment–Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial , 2013, Circulation.

[3]  J. Deckers Classification of myocardial infarction and unstable angina: a re-assessment. , 2013, International journal of cardiology.

[4]  K. Fox,et al.  Risk stratification in non-ST-segment elevation acute coronary syndromes: troponin alone is not enough. , 2009, The American journal of medicine.

[5]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[6]  C. Mueller Biomarkers and acute coronary syndromes: an update. , 2014, European heart journal.

[7]  J. Narula,et al.  Year in Review: Advances in Understanding of Plaque Composition and Treatment Options , 2014 .

[8]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[9]  H. Katus,et al.  High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. , 2010, Clinical chemistry.

[10]  H. Bøtker,et al.  Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. , 2014, European heart journal.

[11]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[12]  J. Narula,et al.  Advances in the understanding of plaque composition and treatment options: year in review. , 2014, Journal of the American College of Cardiology.

[13]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[14]  V. Fuster,et al.  From Treating Complex Coronary Artery Disease to Promoting Cardiovascular Health: Therapeutic Transitions and Challenges, 2010–2020 , 2011, Clinical pharmacology and therapeutics.

[15]  S. Kurz,et al.  Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. , 2012, The American journal of medicine.

[16]  Pierre Croisille,et al.  Effect of cyclosporine on reperfusion injury in acute myocardial infarction. , 2008, The New England journal of medicine.

[17]  C. Kramer Avoiding the imminent plague of troponinitis: the need for reference limits for high-sensitivity cardiac troponin T. , 2014, Journal of the American College of Cardiology.

[18]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[19]  D. Fitzgerald,et al.  Ticlopidine and clopidogrel. , 1999, Circulation.

[20]  C. Hamm,et al.  Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. , 2011, American heart journal.

[21]  V. Fuster,et al.  Coronary artery disease: pathogenesis and acute coronary syndromes. , 2001, The Mount Sinai journal of medicine, New York.

[22]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[23]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[24]  L. Neyses,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[25]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.

[26]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[27]  K. Eagle,et al.  Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.

[28]  S. Jha,et al.  Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. , 2011, Journal of the American College of Cardiology.

[29]  J. Spertus,et al.  ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Am , 2012, Journal of the American College of Cardiology.